INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2019. The put-call ratio across all filers is 2.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $171,000 | +22.1% | 13,146 | +14.1% | 0.02% | -45.5% |
| Q1 2019 | $140,000 | +19.7% | 11,522 | +12.3% | 0.03% | +17.9% |
| Q4 2018 | $117,000 | -64.1% | 10,257 | -31.7% | 0.03% | -56.2% |
| Q3 2018 | $326,000 | +26.4% | 15,026 | +2.9% | 0.06% | +23.1% |
| Q2 2018 | $258,000 | -18.4% | 14,601 | -2.7% | 0.05% | -21.2% |
| Q1 2018 | $316,000 | +39.8% | 15,005 | -3.7% | 0.07% | +50.0% |
| Q4 2017 | $226,000 | +62.6% | 15,588 | +77.3% | 0.04% | +76.0% |
| Q3 2017 | $139,000 | +35.0% | 8,791 | +38.4% | 0.02% | +56.2% |
| Q1 2017 | $103,000 | -31.8% | 6,350 | -36.4% | 0.02% | -30.4% |
| Q4 2016 | $151,000 | +45.2% | 9,979 | +46.9% | 0.02% | +64.3% |
| Q3 2016 | $104,000 | -65.2% | 6,794 | -11.8% | 0.01% | -62.2% |
| Q2 2016 | $299,000 | +75.9% | 7,700 | +25.9% | 0.04% | +76.2% |
| Q1 2016 | $170,000 | -51.6% | 6,114 | -6.2% | 0.02% | -41.7% |
| Q4 2015 | $351,000 | +165.9% | 6,521 | +97.6% | 0.04% | +176.9% |
| Q3 2015 | $132,000 | – | 3,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |